Publications by authors named "William Symonds"

Claim this Profile
A
A trial design to maximize knowledge of the effects of rodatristat ethyl in the treatment of pulmonary arterial hypertension (ELEVATE 2).
Howard M Lazarus, Jill Denning, Stephen Wring, Michelle Palacios, Sidra Hoffman, William Symonds

Pulm Circ· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of sofosbuvir for the treatment of hepatitis C virus infection.
Eric Lawitz, Ira M Jacobson, David R Nelson, Stefan Zeuzem, Mark S Sulkowski, William T Symonds

Ann N Y Acad Sci· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir.
Brian J Kirby, William T Symonds, Brian P Kearney, Anita A Mathias

Clin Pharmacokinet· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis.
K Rajender Reddy, Marc Bourlière, Mark Sulkowski, Masao Omata, Stefan Zeuzem, William Symonds

Hepatology· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failed.
Stanislas Pol, Mark S Sulkowski, Tarek Hassanein, Edward J Gane, Lin Liu, William T Symonds

Hepatology· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.
Masashi Mizokami, Osamu Yokosuka, Tetsuo Takehara, Naoya Sakamoto, Masaaki Korenaga, William T Symonds

Lancet Infect Dis· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry.
Peter J Ruane, Dani Ain, Richard Stryker, Raymond Meshrekey, Mina Soliman, William T Symonds

J Hepatol· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation.
Xavier Forns, Michael Charlton, Jill Denning, John G McHutchison, William T Symonds

Hepatology· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sofosbuvir for chronic hepatitis C virus infection genotype 1-4 in patients coinfected with HIV.
Maribel Rodriguez-Torres, Anuj Gaggar, Gong Shen, Brian Kirby, Evguenia Svarovskaia, William T Symonds

J Acquir Immune Defic Syndr· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
Marc Bourlière, Jean-Pierre Bronowicki, Victor de Ledinghen, Christophe Hézode, Fabien Zoulim, William T Symonds

Lancet Infect Dis· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis.
Eric Lawitz, Fred Poordad, Diana M Brainard, Robert H Hyland, Di An, William T Symonds

Hepatology· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study.
Anita Kohli, Anuoluwapo Osinusi, Zayani Sims, Amy Nelson, Eric G Meissner, William T Symonds

Lancet· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
Michael P Curry, Xavier Forns, Raymond T Chung, Norah A Terrault, Robert Brown, William T Symonds

Gastroenterology· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
Michael Charlton, Edward Gane, Michael P Manns, Robert S Brown, Michael P Curry, William T Symonds

Gastroenterology· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus.
Eric M Yoshida, Mark S Sulkowski, Edward J Gane, Robert W Herring, Vlad Ratziu, William T Symonds

Hepatology· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938.
Jeremie Guedj, Phillip S Pang, Jill Denning, Maribel Rodriguez-Torres, Eric Lawitz, William Symonds

Antivir Ther· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials.
Evguenia S Svarovskaia, Hadas Dvory-Sobol, Neil Parkin, Christy Hebner, Viktoria Gontcharova, William T Symonds

Clin Infect Dis· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.
Eric Lawitz, Mark S Sulkowski, Reem Ghalib, Maribel Rodriguez-Torres, Zobair M Younossi, William T Symonds

Lancet· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial.
Masao Omata, Shuhei Nishiguchi, Yoshiyuki Ueno, Hitoshi Mochizuki, Namiki Izumi, William T Symonds

J Viral Hepat· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.
Mark S Sulkowski, Susanna Naggie, Jacob Lalezari, Walford Jeffrey Fessel, Karam Mounzer, William T Symonds

JAMA· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.
Kris V Kowdley, Stuart C Gordon, K Rajender Reddy, Lorenzo Rossaro, David E Bernstein, William T Symonds

N Engl J Med· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
Nezam Afdhal, Stefan Zeuzem, Paul Kwo, Mario Chojkier, Norman Gitlin, William T Symonds

N Engl J Med· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sofosbuvir and ribavirin in HCV genotypes 2 and 3.
Stefan Zeuzem, Geoffrey M Dusheiko, Riina Salupere, Alessandra Mangia, Robert Flisiak, William T Symonds

N Engl J Med· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
Nezam Afdhal, K Rajender Reddy, David R Nelson, Eric Lawitz, Stuart C Gordon, William T Symonds

N Engl J Med· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
Mark S Sulkowski, David F Gardiner, Maribel Rodriguez-Torres, K Rajender Reddy, Tarek Hassanein, William Symonds

N Engl J Med· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis